Enterprise record

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:d7de8a13-673c-4472-83ea-fb908e9212e0Version: public-1As of: unavailable

9 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 29, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 5 claims
    • Legal Name: Arcturus Therapeutics Holdings Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 29, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 29, 2026

  2. Arcturus Therapeutics Holdings Inc. DEF 14A 2025-04-25

    sec proxy · Source published: Apr 25, 2025 · Retrieved: Apr 24, 2026

    Supports 4 claims
    • Leadership Role: Andy Sassine: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: David Farrell: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: James Barlow: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Joseph E. Payne: Director · Claim reviewed: Sep 29, 2026